APR-246
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions
Acute Myeloid Leukemia or Myelodysplastic Syndromes
Trial Timeline
Sep 16, 2019 → Jan 14, 2022
NCT ID
NCT03931291About APR-246
APR-246 is a phase 2 stage product being developed by Aprea Therapeutics for Acute Myeloid Leukemia or Myelodysplastic Syndromes. The current trial status is completed. This product is registered under clinical trial identifier NCT03931291. Target conditions include Acute Myeloid Leukemia or Myelodysplastic Syndromes.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia or Myelodysplastic Syndromes were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03931291 | Phase 2 | Completed |
| NCT00900614 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia or Myelodysplastic Syndromes